Stable aqueous formulations of adalimumab
View Patent ↗The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A buffered aqueous pharmaceutical composition comprising:
adalimumab;
(ii) buffer; and
(iii) stabilizer;
wherein the composition is free of surfactant, has a pH of about 5 to about 6, and is stable for one week at 40° C. or two weeks at 25° C.
2. The composition of claim 1 wherein the stabilizer is selected from the group consisting of an amino acid, a salt, EDTA and a metal ion.
3. The composition of claim 2 wherein the amino acid is selected from the group consisting of glycine, arginine and combinations thereof.
4. The composition of claim 2 wherein the salt is selected from the group consisting of sodium chloride and sodium sulfate.
5. The composition of claim 4 wherein the salt is, or includes, sodium sulfate.
6. The composition of claim 1 wherein the buffer contains no citrate and consists of histidine, succinate, or a combination thereof; and wherein the composition may further optionally include (i) phosphate acting as a stabilizer and not as a buffer, so that the composition is at pH about 5 to about 6 without phosphate or (ii) polyol; or both.
7. The composition of claim 6 wherein histidine is the sole buffer in the composition; the composition has osmolality of about 180 to 420 mOsM; the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml; and the dosage contains about 10 to 80 mg of adalimumab.
8. The composition of claim 7 wherein the dosage is about 40 mg and results in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer that comprises citrate.
9. A buffered aqueous pharmaceutical composition having pH of about 5 to about 6, comprising:
(i) adalimumab;
(i) buffer, free of citrate, and consisting essentially of histidine, succinate, or both;
(ii) stabilizer consisting essentially of:
(a) glycine, arginine, or both; or
(a) and (b); where (b) is sodium chloride, sodium sulfate or both;
wherein the composition is free of surfactant, and is stable for one week at 40° C. or two weeks at 25° C.
10. The composition of claim 9 comprising histidine as the sole buffer, and glycine.
11. The composition of claim 9 comprising histidine as the sole buffer, and arginine.
12. The composition of claim 9 wherein (b) is, or includes, sodium sulfate.
13. The composition of claim 9 further comprising phosphate acting as a stabilizer and not as a buffer so that the composition is at pH from about 5 to about 6 without phosphate; and, optionally, a polyol.
14. The composition of claim 9 having pH of 5 to 6 and osmolality of about 180 to 420 mOsM; wherein the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml; and the dosage contains about 10 to 80 mg of adalimumab.
15. The composition of claim 14 wherein the dosage is about 40 mg and results in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer comprising citrate.
16. An aqueous buffered pharmaceutical composition comprising adalimumab and a citrate-free buffer, wherein the composition is free or substantially free of a surfactant, has a pH of about 5 to about 6, and is stable for one week at 40° C. or two weeks at 25° C.
17. The composition of claim 16 comprising: (i) adalimumab; (ii) buffer consisting solely of histidine, succinate, or combination thereof; and (iii) glycine, arginine or both.
18. The composition of claim 17 further comprising phosphate acting as a stabilizer and not as a buffer.
19. The composition of claim 17 further comprising a salt selected from sodium chloride and sodium sulfate.
20. The composition of claim 17 having osmolality of about 180 to 420 mOsM; wherein the composition is suitable for administration to a subject as a single dosage; said composition having a concentration of adalimumab in the range of 30 to about 50 mg/ml; said dosage containing about 40 mg of adalimumab and resulting in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer that comprises citrate.